Heartbeam, Inc.

Greetings and welcome to the HeartBeam First Quarter 2026 Financial Results Conference Call. At this time, all participants are in Listen Only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that the statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risk and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflects our opinions only as of date of this presentation. Keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in the light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our prediction. We should also review our most recent Form 10-K and from 10Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon and is available in the Investor Relations section of our company's website, heartbeam.com. Rob Eno, Chief Executive Officer, Tim Cruikshank, Chief Financial Officer, and Brian Humbagger, Chief Commercial Officer, will present results of operation for the first quarter ended March 31st, 2026. At this time, I will turn the call over to HeartBeam Chief Executive Officer, Mr. Rob Eno. Please go ahead.

Thank you, operator. The topics we'll cover on today's call are listed on the slide. We'll start with a brief summary of our recent progress, followed by a reminder of the HeartBeam system and our unique technology platform. Brian Humbarger, our Chief Commercial Officer, will provide an overview of our limited commercial launch. We'll then provide updates on our major growth initiatives, the on-demand 12-lead patch, and our heart attack detection and AI efforts, followed by the financial results. We'll end with Q&A. I'll briefly summarize our recent progress. We'll cover each of these in more detail throughout the presentation. We continue to execute well across both commercialization and our growth initiatives. On commercialization, we signed our first commercial partnership in Q1 with Clear Cardio, anchoring us in New York City, Dallas, and South Florida. We've since added Atelier Health, a Beverly Hills concierge practice led by physicians affiliated with Cedars-Sinai. extending us to Southern California and giving us flagship sites in all four of our target geographies. Together, these partnerships established our initial foothold in the direct pay segment, which represents roughly 5 million U.S. patients. On heart attack detection, we enrolled the first patients in our Align ACS pilot study, which compares heart beam to a standard 12-week ECG in chest pain patients in the emergency department. Enrollment's ahead of schedule. The study is a key step toward FDA indication expansion into a market of 20 million at-risk patients. On the 12-lead patch, we completed our first working prototype in Q1, and we've now initiated a pilot study focused on ischemia detection. We believe this will be the best-in-class patch in a $2 billion market with established reimbursement. Partnership discussions continue to progress. On AI, we announced a strategic collaboration with Mount Sinai pairing their AI and clinical expertise with our 3D ECG signal collection technology to develop next-generation algorithms for heart attack detection, wellness, and personalized cardiac assessment. Before we dive into detailed updates, I want to remind everyone about our initial product, the HeartBeam system, and our platform technology. HeartBeam is dedicated to developing groundbreaking ECG technology for patients to use at home to empower them to feel confident about their heart health. Heartbeam has developed the first ever portable cable-free ECG that can synthesize a 12-lead ECG. Our unique IP-protected approach captures the heart's electrical signals in three dimensions or non-coplanar directions and synthesizes the signals into a 12-lead ECG. The system is designed to be easy to carry and easy for patients to use at the time of symptom onset, anywhere, anytime. The technology is supported by a team of US-based board-certified cardiologists who are available 24-7 to interpret the clinical-grade ECG and triage patients appropriately to ensure timely care. The system has received two FDA clearances for arrhythmia assessment. With these two clearances in place, we're embarking on our limited commercial launch. As you'll hear, we're extremely pleased with the reception of the system among leading concierge physicians and preventive cardiologists. HeartBeam's more than just the first cable-free synthesized 12-lead ECG. It is true platform technology. The major advance that we pioneered and what our key IP is based around is our novel signal collection technology, which captures the heart's electrical signals in three axes, left and right, up and down, and into the body. These 3D signals can be converted into a familiar 12-lead waveform. This core technology can be applied to multiple form factors, We're embarking on the launch of the Heartbeam system, the credit card size form factor. Recently, we announced the second form factor, an on-demand 12-lead extended wear patch. We believe that this patch can disrupt the ambulatory cardiac monitoring market, a $2 billion revenue market. The technology in these two form factors has the potential to enable a full range of 12-lead ECG capabilities, including currently cleared arrhythmia assessment and future indications of heart attack detection and personalized AI algorithms. We'll discuss our progress toward heart attack detection and AI algorithms shortly, but now we want to turn it over to Brian Humbarger, HeartBeam's Chief Commercial Officer, to provide an update on our commercial efforts. Brian?

Thank you, Rob. Our commercial goals remain consistent, and execution of the plan is well underway. As a review, we stated that in the first half of 2026, where we are today, Then we are focused on validating our premium value proposition, refining the heartbeam systems and processes, signing and onboarding our anchor accounts, and proving the scaling efficiency of the model. In the second half of 2026, we will shift to proving deep adoption inside those anchor accounts establishing the funnel that will support our 2027 revenue and adoption goals, developing white papers and clinical proof points to drive further adoption and beginning to expand the sales team around our anchor geographies. And then in 2027 and beyond, we will scale revenue, move to the train the trainer model for implementation, expand our clinical research opportunities and expand the sales, clinical and account management teams. These are the specific goals we set for in the first half of 2026 alongside our status against each one. Our first two goals are focused on signing and onboarding anchor accounts in key targeted markets and executing a concentrated rollout strategy in four key geographies, New York City, Dallas, South Florida, and Southern California. We've now built flagship accounts in all four markets. Since our last call, We've added Atelier Health, located in Beverly Hills and led by physicians affiliated with Cedars-Sinai. This establishes access of the Heartbeam technology in Southern California. Additionally, our first customer, Clear Cardio, has recently expanded its footprint from Dallas to New York and South Florida, bringing along our technology as part of their offering in these markets. These are technology-forward customers that are rapidly growing in the preventative cardiology space. We also set out to validate our premium value proposition. Early physician engagement and flagship account traction have clearly reinforced demand for our personalized 12 lead ECG capability. Physicians who have spent time with the technology are confirming what we've And finally, we prioritize the need to refine physician workflows. We've been working directly with ClearCardio and Atelier on rollout planning, workflow integration, and the implementation processes. And what we are learning is informing a cleaner, faster onboarding playbook. We will continue to prove our ability to scale efficiently. We are demonstrating this by accessing large patient populations through a focused set of strategically selected practices with a lean commercial team. Our focus will be on growth, which is the expansion of heartbeat access in the target geography and adoption, the penetration of patients in our contracted accounts. For the limited commercial launch, we plan to execute this strategy with a sales director and one implementation specialist. After this phase, we plan to have a sales director and one to two implementation specialists per geography to support our growth and adoption efforts. Finally, we will begin measuring growth and adoption in addition to other key metrics as we move into this next phase of commercialization. Now I'll turn it back to Rob.